SHIPPEO
13.10.2021 13:12:05 CEST | Business Wire | Press release
Shippeo , a global leader and European specialist in real-time transportation visibility, announced today 103% year-on-year growth in subscription revenues and 181% net retention rate. The visibility solutions provider maintains the fastest growing customer base in Europe, having expanded its presence globally with the acquisition of several new high-profile customers currently being deployed in North America, Latin America, and APAC.
Since January, Shippeo has welcomed several new large international brands, including Coca-Cola HBC, one of the largest strategic bottling partners of The Coca-Cola Company; Nexans, a global player in energy transition; XPO Logistics, an American freight transportation company; and Woco Group, a global automotive component specialist, who supplies major OEMs.
A number of other category-leading brands have also chosen Shippeo’s real-time visibility solution, including Sappi, a leading producer of coated graphic paper, packaging and specialty papers; Conad, an Italian retail brand operating one of the largest supermarket chains in Italy; Fnac Darty Group, a French multinational electrical retailing company; Studio Moderna, an e-commerce company primarily operating across Central and Eastern Europe; and IDS, a Dutch 4PL logistics control tower specialist.
“Our very high net retention rate is a direct result of customers choosing to take fuller advantage of our expanding product portfolio, which now includes dock visibility and paperless visibility. Our ocean visibility has also become particularly popular as factors including Covid, the Suez blockage, and a global shortage of containers only intensifies the focus on the performance of this critical transport mode,” says Lucien Besse, COO of Shippeo .
“Shippeo has been recognized with a 98% recommendation rate on Gartner Peer Insights by our customers as at October 13, 2021*. I’m particularly proud of this achievement. Nothing is more important to us than delivering value to our customers and this is a fantastic result,” says Besse .
Shippeo’s team has expanded to over 230, with more than 90 new team members joining since January. Shippeo is on track to have more than doubled its staff year-on-year by the end of 2021. In addition, a number of senior profiles joined the company, including Nicolas Doucet, Strategic Alliance Director, previously at PTV Group; Guy-Pascal Bourlard, Head of Quality Assurance, previously at Amazon; Olivier Marcellin, Product Director, previously at Criteo; Marius Neuhäuser, Head of Solution Consulting, Alessandro De Martini, Business Development Director Italy, previously Country Manager at Transporeon and Bas Kramer, Business Development Director Benelux.
Furthermore, Shippeo is now expanding its operations into North America. As part of this strategic expansion, the company has welcomed Christopher Mazza as Senior Vice President, International Growth who will be responsible for leading the company’s activities in the region and growing Shippeo’s customer base. Christopher has extensive experience in the transportation and logistics industry, having participated in the creation of ClearMetal where he played an integral role in business development before joining project44 following the company's acquisition.
Recently the company announced new strategic partnerships with Savoye, a leading designer and integrator of complete supply chain solutions, and Tesisquare, a leading provider of supply chain execution applications. Shippeo has also partnered with Siemens DL, a leading IT provider in global supply chain management solutions.
The collaborations aim to make it easier for customers to overcome transport management challenges by leveraging deep TMS integrations, making it simple to take advantage of real-time visibility’s many benefits.
“We’re incredibly proud of the momentum we’re experiencing and the fact that we’ve maintained 0% customer churn throughout the year,” says Besse . “It’s really thanks to our extremely dedicated teams, our holistic customer-centric approach and a focus on the quality of our solution implementations, relationships and accelerated time to value for customers.”
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation.
Gartner research publications consist of the opinions of
Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom